化合物UM-164 T4597

Product Introduction
Bioactivity


英文名: UM-164

描述: UM-164 (DAS-DFGO-II) 是一种高效的c-Src 抑制剂，Kd 为 2.7 nM。它还抑制p38α和p38β活性。

细胞实验: MDA-MB 231 and SUM 149 cells are plated in triplicate on 60 mm dishes at a density of 1×106 cells/flask. After 24 h, a final concentration of 1 μM UM-164 is added to the cells and incubated for 24 h. Growth medium is then removed and cells are washed with PBS. The remaining cells are trypsinized, harvested, and placed together with growth medium and PBS. Cells are pelleted and re-suspended in 3 mL of 75% ethanol, followed by overnight storage at - 20°C. After incubation, cells are centrifuged at 1,500 rpm for 5 min and the cell pellets are re-suspended in 0.05 mg/mL propidium iodide (10 μg/mL) containing 300 μg/mL RNase. Cell clumps are filtered. Cell DNA content is measured on flow cytometer and cell cycle distribution is calculated from 10,000 cells using FACS analysis[1] .

动物实验: Mice[1]

体外活性: UM-164 is a highly potent inhibitor of c-Src with a binding constant comparable with Dasatinib (UM-164 Kd=2.7 nM, Dasatinib Kd=0.7 nM) in biochemical assays. To confirm that UM-164 is capable of inhibiting the activation of c-Src in vitro, the effect of UM-164 is examined on the c-Src autophosphorylation in two TNBC cell lines (MDA-MB 231 and SUM 149). Inhibition of c-Src autophosphorylation is detected in a concentration- and a time-dependent manner. At 120 minutes, complete abrogation of c-Src autophosphorylation is observed at 50 nM, demonstrating that UM-164 is a potent c-Src inhibitor in vitro. Flow cytometry experiments demonstrate that UM-164 treatment of MDA-MB 231 and SUM 149 increased the proportion of G0-G1 cells by 25% and 28%, respectively, and concurrently decreased the fraction of S cells by 16% and 19%, respectively[1].

体内活性: A xenograft study is performed using NCr/nude mice implanted with MDA-MB 231 and SUM 149 cell lines. After the tumors become palpable, the mice are randomized into control and treatment groups. Mice are injected intraperitoneally with either drug (10 and 20 mg/kg in both xenograft studies; a 15 mg/kg dose is added to the SUM 149 xenograft studies) or vehicle every other day (n=5 for each group). At the selected doses of UM-164, there is no significant weight loss or gross abnormalities observed in the treated animals, even after 52 days of treatment. However, tumor growth is significantly inhibited in both the 10 mg/kg and 20 mg/kg dose groups compared with the vehicle-treated group (P<0.026 and P<0.004, respectively)[1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 6.41 mg/mL (10 mM)


关键字: p38 MAPK | Autophagy | Src | inhibit | UM 164 | Inhibitor | UM-164

相关产品: Isofraxidin | Cytochalasin D | AMG-47a | Skatole | Ciglitazone | Doramapimod | MW-150 | FERULIC ACID METHYL ESTER | BMS-582949 hydrochloride | FR 167653

相关库: HIF-1 Signaling Pathway Compound Library | Anti-Liver Cancer Compound Library | Anti-Cancer Metabolism Compound Library | Bioactive Compounds Library Max | Kinase Inhibitor Library | Inhibitor Library | Cytoskeletal Signaling Pathway Compound Library | Tyrosine Kinase Inhibitor Library | Autophagy Compound Library | Bioactive Compound Library

化合物UM-164 T4597信息由TargetMol中国为您提供，如您想了解更多关于化合物UM-164 T4597报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途